DSDaniel P. Salem

Daniel P. Salem

*This is an algorithmically generated author record based on publicly available information.

Daniel P. Salem has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection of early-stage lung adenocarcinoma using a novel extracellular vesicle and particle-based blood test

    by Ibukunoluwapo O. Zabroski, Daniel P. Salem, Aaron Chevalier, Timothy Santos-Heiman, Nina A. Insixiengmay, Brittany Grimes, Katherine S. Yang, Gabrielle N. Barcaskey, MacKenzie S. King, Syrena C. Fernandes, et al.

    Tumor-derived extracellular vesicles and particles (EVPs) represent a promising analyte class for early cancer detection. However, discrimination of tumor-derived EVPs from those shed by healthy tissues represents a major analytical challenge. This work describes the design and characterization of a novel proximity ligation-based immunoassay which targets tumor-derived EVPs in plasma displaying four colocalized surface biomarkers. We demonstrate the functionality of this approach in cancer cell line-derived EVPs and apply the method to lung adenocarcinoma (LUAD) detection. Importantly, we find that requiring four colocalized cancer-associated biomarkers reduces interference from healthy EVPs versus a three-biomarker design, resulting in strong discrimination performance for several biomarker combinations. Using this approach, we developed a prototype assay for LUAD detection which was evaluated in a case-control study composed of 92 LUAD cases and 290 non-cancer controls. The assay and trained classifier exhibited 48.5% (33/68; 95% confidence interval (CI) 37.1–60.2%) stage I sensitivity, 83.3% (15/18; 95% CI 59.8–94.8%) stage II sensitivity, and 100% (6/6; 95% CI 55.2–100%) stage III/IV sensitivity at 90% specificity. Assay signal was significantly correlated with tumor size and uncorrelated with smoking history. These preliminary results demonstrate the technical feasibility of this platform for early-stage lung cancer detection.

  • Open Access

    Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer

    by Daniel P. Salem, Laura T. Bortolin, Dan Gusenleitner, Jonian Grosha, Ibukunoluwapo O. Zabroski, Kelly M. Biette, Sanchari Banerjee, Christopher R. Sedlak, Delaney M. Byrne, Bilal F. Hamzeh, et al.


  • Open Access

    Colocalization of Cancer Associated Biomarkers on Single Extracellular Vesicles for Early Cancer Detection

    by Daniel P. Salem, Laura T. Bortolin, Dan Gusenleitner, Jonian Grosha, Ibukunoluwapo O. Zabroski, Kelly M. Biette, Sanchari Banerjee, Christopher R. Sedlak, Delaney M. Byrne, Bilal F. Hamzeh, et al.

    Detection of cancer early, when it is most treatable, remains a significant challenge due to the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. Detection of their presence is made more difficult by a lack of abundant tumor-specific indicators (i.e., protein biomarkers, circulating tumor DNA, etc.) that would enable detection using a non-invasive diagnostic assay. In addition, many benign conditions manifest in a similar manner, thus discriminating an early-stage cancerous lesion from a benign tumor can present additional challenges and result in unnecessary medical procedures. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. Extracellular vesicles from all cell types, including early-stage tumors, are known to be abundant in blood, are remarkably stable, and serve as a biopsy of their cell of origin. The detection of a colocalized combination of cancer associated biomarkers that provide tumor specificity on the surface of extracellular vesicles enables the discrimination of early- and late-stage cancer from non-malignant conditions.